COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223)

Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density

Purpose: The aim of this study was to investigate the effect of topical 0.1% olopatadine hydrochloride on goblet cell density, clinical signs, and symptoms of patients with vernal keratoconjunctivitis

An experimental study on the effect of collagen shields and therapeutic contact lenses on corneal wound healing.

We evaluated the effects of collagen shields and therapeutic contact lenses on corneal wound healing in rabbits. A corneal wound was created by mechanical removal of the central 6-mm zone of the corneal epithelium and basement membrane in 30 eyes of 15 rabbits. The animals were divided into three groups: five rabbits in the first group were treated with a collagen shield in one eye and a therapeutic lens in the other eye. In the remaining two groups, either a collagen shield or a therapeutic lens was applied in one eye and the other eye served as the control. The radius and area of the wound were measured at 0, 6, 24, and 48 h after wounding. Linear regression analysis revealed a significant reduction in the wound area with time in all groups. The healing rate was found to be 0.52+/-0.08 mm(2)/h in the collagen shield, 0.54+/-0.05 mm(2)/h in the therapeutic lens, and 0.43+/-0.06 mm(2)/h in the control group. Comparison of the study groups by Bonferroni modification of analysis of variance revealed no statistically significant difference between the collagen shield and the therapeutic lens group at any time (p > 0.05), whereas a significantly larger wound size was observed in the control group compared with the treatment groups at all times studied (p < 0.05 at 6 h; p < 0.001 at 24 and 48 h). In conclusion, our results indicate that both collagen shields and therapeutic lenses enhance wound healing in rabbit eyes